Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029642 | 0.89 | RXRA (0.48) | RXRA | |
| SCHEMBL6029646 | 0.84 | RXRA (0.52) | RXRA | |
| SCHEMBL6029652 | 0.84 | RXRA (0.52) | RXRA | |
| SCHEMBL5484727 | 0.75 | RXRA (0.52) | RXRA | |
| SCHEMBL6028226 | 0.74 | RXRA (0.63) | RXRA | |
| SCHEMBL6028228 | 0.74 | RXRA (0.63) | RXRA | |
| SCHEMBL5657029 | 0.73 | RXRA (0.39) | RXRA | |
| SCHEMBL5655055 | 0.73 | RXRA (0.41) | RXRA | |
| SCHEMBL5657416 | 0.73 | RXRA (0.38) | RXRA | |
| SCHEMBL5658300 | 0.71 | RXRA (0.40) | RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1643993-A2 | SUBSTITUTED ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS, CANCER AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | disclosed |
| WO-2004093809-A2 | SUBSTITUTED ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS, CANCER AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | HSD17B10, IDH2, INSR | RXRA 1054/4885CYP1A2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.